Clinical Trials Logo
  1. Home
  2. Dystrophic Epidermolysis Bullosa
  3. NCT01768026

Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa Clinical Trial

Official title:
A Prospective, Longitudinal Assessment of Disease Severity in Subjects With Dystrophic Epidermolysis Bullosa (DEB)

Clinical Trial Summary

The objective of this study is to characterize the extent and severity of disease in subjects with DEB and the progression of disease over a timeframe relevant to interventional studies. The data from this study will be used to inform the study design and address statistical considerations of future treatment protocols.

Clinical Trial Description

This is a prospective, multicenter, multinational, longitudinal assessment of disease severity in subjects with DEB. Subjects with either dominant or recessive DEB (dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB), respectively) will be assessed four times over a one year period: upon enrollment, and at 1 to 2 weeks and 6 and 12 months after enrollment. All subjects with either DDEB or RDEB that meet the study entry criteria will be offered participation in the study, provided they can be accommodated within the anticipated study timeline. In addition to their usual clinic assessment, subjects will have a quantitative evaluation of skin involvement and will be asked to fill out questionnaires that measure among other things disease severity, QOL, pain, pruritus, and medical and family histories. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01768026
Study type Observational
Source Lotus Tissue Repair, Inc.
Contact
Status Withdrawn
Phase N/A
Start date February 2013
Completion date September 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT03536143 - A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients Phase 1/Phase 2
Recruiting NCT04917887 - Long-Term Follow-up Protocol
Completed NCT04917874 - A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa Phase 3
Terminated NCT03578029 - Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa Phase 2
Completed NCT03472287 - To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) Phase 1
Recruiting NCT05157958 - Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa Phase 2
Withdrawn NCT01528306 - A Pilot Study of HP802-247 in Dystrophic Epidermolysis Bullosa Phase 2
Completed NCT02178969 - Short Term Observational Study in DEB Patients
Withdrawn NCT04214002 - The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Recruiting NCT04757727 - Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)
Completed NCT01538862 - Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa N/A
Completed NCT03183934 - A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial
Completed NCT02579369 - Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa Phase 1/Phase 2
Withdrawn NCT02004600 - Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB N/A
Completed NCT04491604 - Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB Phase 3
Not yet recruiting NCT05529134 - Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene Phase 1/Phase 2
Not yet recruiting NCT04173650 - MSC EVs in Dystrophic Epidermolysis Bullosa Phase 1/Phase 2